BeyondSpring Reports $5.7 Million Net Loss in Q2 2026, Focuses on Plinabulin Development

BeyondSpring Inc. reported a consolidated net loss of $5.7 million for the second quarter of 2026, compared to a loss of $4.6 million in the same period of the previous year. For the first half of 2026, the company’s net loss increased significantly to $12.4 million from $3.5 million in the prior year. The company continues to operate without generating any revenue from product sales, maintaining an accumulated deficit of $411.4 million as of June 30, 2026. Operating expenses for the second quarter included $973,000 in research and development and $758,000 in general and administrative costs, reflecting a decrease in G&A expenses compared to the previous year.

In terms of operational changes, BeyondSpring has been focusing on its lead asset, Plinabulin, which is in clinical development for various cancer indications. The company is preparing for a confirmatory global Phase 3 study (DUBLIN-4) following the successful completion of the DUBLIN-3 study, which demonstrated significant overall survival benefits for patients with non-small cell lung cancer (NSCLC). The company has also been involved in several investigator-initiated studies to further explore Plinabulin's efficacy in combination with other therapies.

The company’s financial position has been impacted by its strategic decision to divest a significant portion of its interests in SEED Therapeutics, which has been classified as discontinued operations. As of June 30, 2026, BeyondSpring expects to retain approximately 38.03% of SEED's outstanding equity, which will decrease to 26.56% and 13.62% after the second and third closings of the sale of Series A-1 Preferred Shares, respectively. This divestiture is part of a broader strategy to optimize resources and focus on its core pipeline.

BeyondSpring's cash and cash equivalents stood at $2.7 million as of June 30, 2026, down from $7.8 million at the end of 2025. The company reported net cash used in operating activities of $7.1 million for the first half of 2026, a decrease from $10.1 million in the same period of 2025. The company is actively exploring various financing options to support its operations, including equity and debt financing, as well as potential licensing and partnership arrangements. The ongoing need for substantial funding raises concerns about the company's ability to continue as a going concern if it cannot secure the necessary capital.